COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Cencora (COR) is transitioning from a bulk pharmaceutical distributor to a specialty medicines infrastructure provider, targeting higher-margin, service-driven growth. Recent acquisitions of OneOncology and Retina Consultants of America are driving margin expansion, with Q2 adjusted gross profit up 15.7% and margin rising to 4.31%. Management raised FY2026 adjusted EPS guidance to $17.70–$17.90, expects $3B adjusted FCF, and targets 10–14% long-term EPS growth.
| Consumer Staples Distribution & Retail Industry | Consumer Staples Sector | Robert Mauch CEO | XWBO Exchange | US03073E1055 ISIN |
| US Country | 51,000 Employees | 1 Jun 2026 Last Dividend | 16 Jun 2009 Last Split | 4 Apr 1995 IPO Date |
Cencora, Inc., previously known as AmerisourceBergen Corporation, is a global leader in healthcare solutions, with a focus on improving patient outcomes through the efficient distribution and commercialization of pharmaceuticals and healthcare-related products. Established in 2001 and headquartered in Conshohocken, Pennsylvania, Cencora has expanded its reach by providing a wide range of services to various healthcare providers, including acute care hospitals, retail pharmacies, mail order pharmacies, and specialists across numerous disease states. The company's commitment to offering comprehensive supply chain management services, specialized software, and consulting services underscores its integral role in the healthcare sector. Through its U.S. Healthcare Solutions and International Healthcare Solutions segments, Cencora, Inc. addresses the nuanced needs of its global client base, delivering tailored services that encompass distribution, commercialization, logistics, and much more.